Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Bone Metastases in Metastatic Renal Cell Carcinoma: Now We Know That Cabozantinib Targets Bone Microenvironment
*Corresponding Author:
Copyright: © 2020 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
To read the full article Peer-reviewed Article PDF 
Abstract
The multiple tyrosine kinases inhibitor cabozantinib has shown improvements in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in comparison to everolimus in patients with metastatic renal cell carcinoma (mRCC) within the METEOR trial, a phase III clinical trial , randomized, open-label trial [1,2], resulting in its approval in mRCC patients previously treated with antiangiogenic agents.
